AG Marcelin, MM Santoro, C. Charpentier, A. Storto, D. Di Carlo, W. Gennari, CF Perno, V. Calvez, D. Descamps, F. Ceccherini-Silberstein. Presented at the 15th European Meeting on HIV & Hepatitis, Rome, Italy, June 7, 2017. (Click here to view the full abstract.)

Citation: "...results suggest that the prevalence of DOR-associated mutations in HIV-1-infected treatment-naïve patients is very low and significantly lower than EFV or RPV-associated mutations. In addition, the prevalence of DOR-associated mutations in this population of patients was stable over time and there was no relationship between the presence of DOR-associated mutation and HIV-1 subtype. ...”